DMPK Project Support
Making sure you implement a strategic DMPK approach at the start of your project will help you identify molecules with drug-like properties that will enable you to progress into the clinic with confidence. By mitigating DMPK risks early, it will simplify and streamline your clinical development plan.
At Apconix our DMPK associates have a breadth of experience
In delivering drug candidates across a range of therapeutic areas and stages of Research and Development. Apconix can deliver personalised DMPK strategies ensuring you adopt a focussed approach to your drug projects. At Apconix we can support you to do the right studies, at the right time to move your drug molecules forward. Depending on the stage of your project, Apconix can guide you through the most appropriate data cascades to deliver your objectives through a wide range of both In vitro and In vivo studies. Our DMPK associates have the experience to interpret the data, provide risk mitigation plans as required and contextualise the data package as a whole for further clinical development.
Our DMPK Scientists
Dr Sarah Pass
PhD
Sarah is an experienced drug metabolism and pharmacokinetics (DMPK) consultant, having worked for almost 30 years in the pharmaceutical and CRO industries, providing a wide range of expertise to academia, biotechnology and pharmaceutical companies. A collaborative project leader, Sarah has broad experience ranging from lead identification though to end of Phase II clinical development. Sarah is passionate about making a difference to patients’ lives and delivering decision-making data to accelerate new drugs through the R&D pipeline.
Dr Peter Ballard
PhD
Peter is a senior drug metabolism and pharmacokinetic (DMPK) expert with extensive experience in global discovery and development projects. He has a proven track record of international project delivery from early drug discovery through to development and compound registration from over 30 years in the pharmaceutical industry and has maintained a high academic profile with more than 30 publications in peer reviewed journals and presentations at international conference.
Dr Tanya Coleman
PhD
Tanya has more than 20 years’ experience in pharmaceutical project teams as a nonclinical ADME specialist and clinical pharmacologist. She held project and team leader roles at several large pharma companies before becoming an independent consultant. In these roles, she has supported research teams as well as early and late clinical development projects, with a particular strength in oncology and infection. Tanya has also led specialist groups in in vitro metabolism and drug transporters.